Lanterne Dx is a CAP-accredited and CLIA-certified full-service histopathology contract research organization (CRO) offering medically relevant non-clinical and clinical services to the pharmaceutical, biotech, and academic communities. Established in 2019, LDX’s 4500 sf laboratory is a state-of-the-art facility equipped to meet your end-to-end research needs. 

Comprised of PhD scientists, DVM and MD pathologists, image analysts, and certified histotechnicians, the LDX team provides expertise and guidance in developing individualized biomarker strategies for clients. 

Lanterne Dx’s capabilities include qualitative and quantitative IHC, IF, ISH, and microscopic applications. We deliver pre- and post-intervention analysis of clinically derived materials for diagnostics and characterization of anti-tumor efficacy endpoints. As a valuable complement to the IHC services, LDX also offers the latest imaging technology with high-throughput brightfield and IF whole-slide scanners, image analysis software, and secure cloud-based image hosting.


Biotechnology

Life Sciences

Pharmaceutical

Lanterne Dx

Lanterne Dx's headquarters in Boulder, United States

Description

People (5)

Jon Bishop

Susan Johnson

Sara Sheppard McCracken

Mary Lou Rath

Bhavika Patel

Jobs